☰
Biothera Pharmaceuticals, Inc., a renowned Minnesota based biotechnology company, reportedly announced that clinical benefit data and updated response from its Phase 2 study in chemo-refractory mTNBC (metastatic triple negative breast cancer) patients would be presented in a Spotlight Session during the 2019 San Antonio Breast Cancer Symposium (SABCS).
The Phase 2 study evaluates Biothera’s Imprime PGG, which is a systematically delivered dectin receptor triggering anti-cancer immune responses, with the anti-PD-1 therapy developed by Merck, KEYTRUDA® (pembrolizumab). The participants of the study were not treated earlier using immune checkpoint inhibitors. They also were identified as positive biomarker for Imprime PGG therapy.
Jeremy Graff, Ph.D., President and Chief Scientific Officer, Biothera Pharmaceuticals, reportedly stated that the clinical data showed compelling evidence from the combination of KEYTRUDA and Imprime PGG in chemo refractory mTNBC patients. Graff further added that the translational data not just delivers proof of concept at the cellular and molecular level, but also offers valuable insights regarding the next steps for clinical development of Imprime PGG.
Latest data from IMPRIME 1 showcased at SABCS depicted 15.9% overall response rate in mTNBC patients that were treated with the combination of KEYTRUDA and Imprime PGG.
Most of the patients showed target lesion stabilization or reduction. The discontinuation of treatment frequently resulted from increase in non-target lesion or new lesions, even when target lesions were stable or shrinking. Patients with such mixed response pattern showed an overall increase in survival.
About Biothera Pharmaceuticals:
Biothera Pharmaceuticals is a renowned biotechnology company headquartered in Minnesota. The firm is committed in developing CPIs, or immune checkpoint inhibitors in combination with Imprime PGG in multiple Phase 2 cancer indications. Its focus is on population of patients and types of tumor wherein single agent CPI therapy provides limited benefits. The types of tumor include non-small cell lung cancer, metastatic triple negative breast cancer, CPI-failed advanced melanoma and colorectal cancer.
Meta, the leading American technology company and the owner of social media platforms Facebook and Instagram, has reportedly announced its plans to lay off around 10,000 employees. Apparently, this is going to be the second round of significant la...
Heathrow Airport, the U.K.’s leading international airport, has reportedly been advised to reduce passenger costs for airlines next year, as they would have an impact on ticket pricing. The Civil Aviation Authority (CAA) determined that lowe...
Amazon, the U.S.-based e-commerce giant, has reportedly inked a deal with struggling mortgage lender, Better.com to provide better perks to employees. For the unversed, Better.com is introducing Equity Unlocker, a product that enables staff member...
© 2024 IntelligenceJournal.com. All Rights Reserved.
